Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2022 07:00 ET | Source: Albireo Pharma, Inc.

Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome

Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial improvements in...
October 05, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients with all types of PFIC – One abstract describes...
September 27, 2022 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
September 22, 2022 08:30 ET | Source: Albireo Pharma, Inc.

Albireo Announces $115 Million Royalty Monetization Agreement with Sagard

Upfront payment for continued clinical development and commercialization of Bylvay® Sagard to receive a mid-single digit average royalty rate on Bylvay sales No liens against Bylvay intellectual...
September 20, 2022 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Participate in Guggenheim Nantucket Therapeutics Conference

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
September 06, 2022 08:00 ET | Source: Albireo Pharma, Inc.

Italian Medicines Agency Approves Reimbursed Access to Bylvay® (odevixibat) For Patients with All PFIC Types

Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that affects...
September 06, 2022 08:00 ET | Source: Albireo Pharma, Inc.

L'Agenzia Italiana del Farmaco approva il rimborso di Bylvay® (odevixibat) per i pazienti affetti da tutti i tipi di Colestasi Intraepatica Familiare Progressiva (PFIC)

La decisione positiva dell'Agenzia Italiana del Farmaco (AIFA) consente l'accesso al rimborso per il primo farmaco disponibile per il trattamento di tutti i tipi di PFIC, una malattia del fegato...
September 01, 2022 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Participate in Upcoming Investor Conferences

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
August 22, 2022 17:13 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the grant of inducement restricted...
August 15, 2022 16:05 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q2 2022 Financial Results and Business Update

Bylvay®(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 millionAgreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fallGlobal Phase 3...